New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Tvardi Therapeutics, Inc.

TVRD

Healthcare Biotechnology

Tvardi Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $7.1 million, down 66.0% from fiscal 2023.

Revenue
+20.3%
EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

0.99 0.04 +4.21%

After hours trading: 0.97, down 2.02%, last trade Fri 7:28pm Eastern.

Market cap
$12.6M
P/E
n/m
Fwd P/E FY25e
n/m
Dividend yield
—
F-score
3/9
ROIC
0.00%
Net debt / EBITDA
1.1×
Payout ratio
—

What it owns vs. what it owes Q3 FY2026, Sep 30, 2026

Shareholders’ equity is 65.7% of the balance sheet. What is a balance sheet?

Sep 30, 2026 · total $23.5M

Owns

$403.0KLong-term assets
$855.0KOther short-term assets
$22.3MCash & short-term investments

Funded by

$15.5MShareholders’ equity
$8.1MOther liabilities

Debt is 0.00% of the total; shareholders’ equity 65.7%.

Sep '26 Jun '26 Mar '26 Dec '25 Older periods
Total current assets
23.13 17.07 25.33 31.54
Total non-current assets
0.40 0.45 0.49 0.54
Total Assets
23.53 17.52 25.82 32.07
Total current liabilities
8.08 9.11 11.26 11.04
Total non-current liabilities
— 0.02 0.05 0.09
Total liabilities
8.08 9.14 11.31 11.13
Common Equity (Total)
15.46 8.38 14.51 20.95
Shareholders Equity (Total)
15.46 8.38 14.51 20.95

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 17, 2026